This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Gilead To Present Data On Oncology Pipeline At American Society Of Hematology Annual Meeting

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that 10 abstracts describing the company's investigational agents for several hematological malignancies have been selected for presentation at the Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10 in New Orleans. The abstracts describe clinical and pre-clinical data from studies of idelalisib, which is currently under review by the U.S. Food and Drug Administration for treatment of refractory indolent non-Hodgkin’s lymphoma (iNHL), as well as for GS-9973, GS-9820 and momelotinib (formerly CYT387 / GS-0387). Detailed results from these studies will be presented at the conference.

“We are encouraged by the data across our hematologic oncology pipeline that will be presented at the ASH annual meeting,” said Roy Baynes, MD, PhD, Senior Vice President of Oncology and Inflammation Therapeutics at Gilead Sciences. “We are moving forward quickly to fully explore the potential clinical benefit of idelalisib and other investigational agents against a range of hematological cancers.”

Presentations on idelalisib, Gilead's investigational, targeted, oral inhibitor of PI3K delta include:

  • Updated data from a Phase 2 study (Study 101-09) in patients with highly refractory iNHL (#85). The results of this trial support Gilead’s regulatory filings for idelalisib for the treatment of iNHL.
  • Analyses from a Phase 1b study (Study 101-07) of idelalisib in combination with currently approved therapies for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) (#4180, #4176 and #2878).
  • An analysis from Phase 1b and 2 studies (Studies 101-07 and 101-08) comparing responses among CLL patients with high risk prognostic markers (Del(17p)/TP53 mutation, Del(11q), IgHV mutation and NOTCH1 mutation) to CLL patients without these markers (#1632).
  • The first pre-clinical data demonstrating the potential of idelalisib for the treatment of myelofibrosis (#4065).

Clinical data on other oral investigational compounds in development for the treatment of hematologic malignancies also will be presented, including:

  • Momelotinib, a selective inhibitor of JAK1 and JAK2: Updated safety and efficacy results from a Phase 1/2 study in myelofibrosis (#108). The Phase 3 clinical program for momelotinib will be initiated this quarter.
  • GS-9973, a selective inhibitor of spleen tyrosine kinase (Syk): Initial results from a Phase 2 study in CLL and non-Hodgkin lymphoma (NHL) (#1634). GS-9973 is being evaluated in Phase 2 studies as both a single agent (Study 102) and in combination with idelalisib (Study 103) in patients with relapsed or refractory CLL, iNHL and other lymphoid malignancies.
  • GS-9820, a second-generation inhibitor of PI3K delta: Data from a Phase 1b dose escalation monotherapy study for recurrent CLL or iNHL (#2881).

Abstracts for Gilead's presentations can be accessed at http://www.hematology.org/Meetings/Annual-Meeting/. Further information about the clinical studies described above can be found at  www.clinicaltrials.gov.

Idelalisib, momelotinib, GS-9973 and GS-9820, each as single-agents and in combination with other agents, are investigational products, and their safety and efficacy have not been established.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs